Correspondence 0001493152-25-004493 from Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD.
Date: Jan. 31, 2025 · CIK: 0001962011 · Accession: 0001493152-25-004493
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284569
Letter
KAIROS PHARMA LTD.
Westwood Blvd., #139
Los Angeles CA 90064
(310) 948-2356
January 31, 2025
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Re: Kairos Pharma, Ltd.
Registration Statement on Form S-1
File No. 333-284569
Acceleration Request
Requested Date: February 4, 2025
Requested Time: 5:00 PM Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Kairos Pharma, Ltd. (the “Registrant”) hereby requests acceleration of the effective date of its registration statement on Form S-1 (File No. 333-284569) so that it may become effective at 5:00 p.m. Eastern Time on February 4, 2025, or at such time as the Registrant may request by telephone to the staff (the “Staff”) of the Securities and Exchange Commission. In addition, the Registrant hereby authorizes Megan J. Penick, Esq. of Dorsey & Whitney LLP, counsel for the Registrant, to make such request on the Registrant’s behalf.
Very
truly yours,
Kairos
Pharma, Ltd.
Show Raw Text
CORRESP
1
filename1.htm
KAIROS
PHARMA LTD.
2355
Westwood Blvd., #139
Los
Angeles CA 90064
(310)
948-2356
January
31, 2025
Via
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Re:
Kairos
Pharma, Ltd.
Registration
Statement on Form S-1
File
No. 333-284569
Acceleration
Request
Requested
Date:
February
4, 2025
Requested
Time:
5:00
PM Eastern Time
Ladies
and Gentlemen:
Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, Kairos Pharma, Ltd. (the “Registrant”) hereby requests
acceleration of the effective date of its registration statement on Form S-1 (File No. 333-284569) so that it may become effective at
5:00 p.m. Eastern Time on February 4, 2025, or at such time as the Registrant may request by telephone to the staff (the “Staff”)
of the Securities and Exchange Commission. In addition, the Registrant hereby authorizes Megan J. Penick, Esq. of Dorsey & Whitney
LLP, counsel for the Registrant, to make such request on the Registrant’s behalf.
Very
truly yours,
Kairos
Pharma, Ltd.
By:
/s/
John S. Yu
Name:
John
S. Yu
Title:
Chief
Executive Officer and
Chairman
of the Board of Directors